Antibody Dependent Cellular Cytotoxicity - a Neglected Anti-HIV Immune Response!

Project Details

The importance of HIV-specific Antibody-dependent Cellular Cytotoxicity (ADCC) antibodies that inhibit viral replication mediated through the Fc receptor is becoming clear. In view of the difficulty of inducing broad neutralizing antibodies and effective T cell immunity, exploring HIV-specific ADCC is a priority. HIV-specific ADCC has been under-explored both from the point of view of rapid, reliable assays to measure and characterize ADCC responses and the ability to specifically induce high level HIV-specific ADCC antibodies by vaccination. Recent data from the RV144 vaccine study in Thailand suggest a role for non-neutralising antibodies in protection from HIV.

CD56+ CD3- Natural Killer lymphocytes expressing IFNϒ in response to HIV+ serum and ADCC peptide epitope within Vpu. No IFNg is expressed to no peptide, an irrelevant peptide, or the absence of IgG.

Figure 1: CD56+ CD3- Natural Killer lymphocytes expressing IFNϒ in response to HIV+ serum and ADCC peptide epitope within Vpu. No IFNg is expressed to no peptide, an irrelevant peptide, or the absence of IgG.

We identified a simple flow cytometry technique to identify HIV-specific ADCC responses and map ADCC epitopes. In its simplest form, small volumes (200ul) of whole blood from HIV-infected subjects are stimulated for 6hr with Env protein or overlapping Env 15mer peptides (or whole Env proteins), and CD56+ NK lymphocytes assessed for expressing the cytokine IFN-y and/or the degranulation marker CD107a. The activity is mediated by IgG antibodies in plasma and the assay can be performed on stored plasma samples using donor blood or PBMC as effector NK cells. The ADCC epitopes can readily be finely mapped to individual peptides from within an overlapping set. The ability of the HIV-specific ADCC antibodies to trigger "polyfunctional" NK cells (e.g. express TNF-alpha, degranulated perforin or granzymes, express chemokines) is also readily monitored in this assay since the NK cells can be accurately gated on. We recently showed ADCC antibodies trigger very rapid activation of NK cells (Chung et al, Journal of Immunology, 2009), which could be important in limiting virus spread. We are now endeavoring to isolate specific ADCC antibodies and identify the most effective antibodies to use in passive transfer studies. We recently wrote a lay review of this area.

Exciting data shows that HIV-specific ADCC responses can force immune escape. This strongly suggests ADCC applies significant pressure to HIV. This was published in PNAS and attracted some media interest here. Reports appeared in The Age and Science Illustrated amongst others. We also recent found that people with HIV that progress more slowly to AIDS have enhanced ADCC responses to specific parts of HIV (see here). Dr Matt Parsons joined our group to study the role of NK cells in the ADCC process (see here). Dr Marit Kramski together with Wen Shi Lee and collaborators at the Alfred hospital is now investigating how ADCC might help clear cell with latent HIV and thus help in the search for a HIV cure - we recently wrote a review in this area (see here). We have also recently started a collaboration with the National AIDS Research Institute in India to study ADCC immunity to HIV.

Researchers

Dr Ivan Stratov, Dr Marit Kramski, Dr Matt Parsons, Ms Vijaya Madhavi, Mr Wen Shi Lee

Funding

NHMRC Project Grant #1034770, Australian Centre for HIV and Hepatitis Virology, Australia-India Strategic Research Fund.

Research Group

Kent Laboratory: HIV Vaccines; Immune Responses to HIV-1; Immunotherapy



Faculty Research Themes

Infection and Immunology

School Research Themes

Infection & Immunity, Molecular Mechanisms of Disease



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Microbiology and Immunology